Cabaletta Bio, Inc.

CABA Nasdaq SEC CIK 1759138
Follow Cabaletta Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$53.1M −18.2% vs same quarter last year
EPS, diluted −$0.28 +36.4% vs same quarter last year
Operating cash flow −$42.7M −23.9% vs same quarter last year
Operating income −$54.7M −17.4% vs same quarter last year
Net income by quarter
−$32.6M
−$35.9M
−$45.1M
−$44.9M
−$41.9M
−$43.5M
−$51M
−$53.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$200M−$150M−$100M−$50M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$167.9M
FY24−$115.9M
FY23−$67.7M
FY22−$53M
FY21−$46.3M
FY20−$33.3M
FY19−$16.9M
FY18−$12.2M
FY17-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$132.3M
FY24−$90.4M
FY23−$54.2M
FY22−$48.8M
FY21−$35.3M
FY20−$27.4M
FY19−$16.7M
FY18-
FY17-